Tower Research Capital (TRC)
BJDX icon

Tower Research Capital (TRC)’s Bluejay Diagnostics BJDX Stock Holding History

Tower Research Capital (TRC)’s Portfolio BJDX Stock Details BJDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.29K Buy
477
+45
+10% +$466 ﹤0.01% 4693
2026
Q1 		$3.18K Buy
432
+155
+56% +$1.53K ﹤0.01% 4354
2025
Q4 		$2.96K Sell
277
-1
-0.4% -$26 ﹤0.01% 4444
2025
Q3 		$6.76K Buy
278
+136
+96% +$3.28K ﹤0.01% 4144
2025
Q2 		$3.91K Buy
142
+33
+30% +$1.08K ﹤0.01% 4413
2025
Q1 		$6.49K Buy
109
+74
+211% +$4.54K ﹤0.01% 4038
2024
Q4 		$2.7K Buy
35
+26
+289% +$1.94K ﹤0.01% 4790
2024
Q3 		$907 Buy
9
+4
+80% +$1.15K ﹤0.01% 5234
2024
Q2 		$3.01K Buy
5
+4
+400% +$13.4K ﹤0.01% 4939
2024
Q1 		$5.76K Hold
1
– – ﹤0.01% 4494
2023
Q4 		$3.97K Buy
+1
New +$21.7K ﹤0.01% 5017
2023
Q3 		– Hold
0
– – – 4628
2023
Q2 		– Hold
0
– – – 5170
2023
Q1 		– Hold
0
– – – 5047
2022
Q4 		– Hold
0
– – – 4979
2022
Q3 		– Hold
0
– – – 4635
2022
Q2 		– Hold
0
– -$8K – 6074
2022
Q1 		– Hold
0
– – – 4560
2021
Q4 		– Hold
0
– – – 5787

Other funds holding BJDX

Armistice Capital
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Heights Capital Management
Heights Capital Management San Francisco, California $433M AUM 8.59% 1-Year Est. Return
Boothbay Fund Management
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
L1 Global Manager
L1 Global Manager Melbourne $142M AUM
Caitong International Asset Management
Caitong International Asset Management Hong Kong $1.04B AUM 150.26% 1-Year Est. Return

Tower Research Capital (TRC)'s BJDX Position: Q2 2026 in Review

Tower Research Capital (TRC) increased its Bluejay Diagnostics (BJDX) stake by 10% in Q2 2026, buying an estimated $466 and bringing the position to 477 shares worth $2.29K. The position accounts for ﹤0.01% of the portfolio, ranked #4693.

Tower Research Capital (TRC) first reported a position in BJDX in Q4 2023 and has held it in 11 quarters since. The position peaked at $6.76K in Q3 2025. 7 funds tracked by Wall St. Rank hold BJDX as of Q2 2026.

  • Tower Research Capital (TRC) held 477 shares of Bluejay Diagnostics worth $2.29K as of Q2 2026.
  • Tower Research Capital (TRC) bought 45 Bluejay Diagnostics shares in Q2 2026, an estimated $466.
  • Bluejay Diagnostics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #4693 holding.
  • Tower Research Capital (TRC) first reported a position in Bluejay Diagnostics in Q4 2023 and has held it in 11 quarters since.
  • Tower Research Capital (TRC)'s Bluejay Diagnostics position peaked at $6.76K in Q3 2025.
  • 7 funds tracked by Wall St. Rank held Bluejay Diagnostics as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.